Literature DB >> 17054549

Urban-rural differences in the management of screen-detected invasive breast cancer and ductal carcinoma in situ in victoria.

David L Kok1, Jiun-Horng Chang, Bircan Erbas, Ashley Fletcher, Anne M Kavanagh, Michael A Henderson, Dorota M Gertig.   

Abstract

BACKGROUND: At least one-third of primary breast cancers in Australia are discovered by population-based mammographic screening. The aim of this study was to determine whether there were any differences in the surgical treatment of women diagnosed with breast cancer by BreastScreen Victoria between urban and rural populations and to investigate temporal changes in their pattern of care.
METHODS: An analysis of women diagnosed with breast cancer (invasive and non-invasive) by BreastScreen Victoria from 1993 to 2000 was conducted. Descriptive analyses of the proportion of women undergoing each surgical treatment type over time were carried out. Logistic regression was used to assess the effect of urban-rural residence on each treatment outcome while accounting for possible confounding factors.
RESULTS: Rural women with invasive breast cancer were less likely to undergo breast-conserving surgery (BCS) compared with urban women (odds ratio, 0.42; 95% confidence interval, 0.35-0.50). The same was also true for rural women with ductal carcinoma in situ (odds ratio, 0.53; 95% confidence interval, 0.29-0.96). This difference was independent of patient and tumour characteristics, including tumour size, surgeon caseload, patient's age and socioeconomic status. It also persisted over time despite a steady overall increase in use of BCS for both invasive and non-invasive cancers over the study period.
CONCLUSIONS: Among Victorian women with screen-detected breast cancer, urban women consistently had higher rates of BCS compared with rural women despite increased overall adoption of BCS. Reasons for this disparity are still unclear and warrant further investigation.

Entities:  

Mesh:

Year:  2006        PMID: 17054549     DOI: 10.1111/j.1445-2197.2006.03917.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  6 in total

1.  Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British Columbia.

Authors:  Benny Lee; Ozge Goktepe; Kevin Hay; Joseph M Connors; Laurie H Sehn; Kerry J Savage; Tamara Shenkier; Richard Klasa; Alina Gerrie; Diego Villa
Journal:  Oncologist       Date:  2014-02-25

2.  Breast cancer treatment and survival differences in women in remote and socioeconomically disadvantaged areas, as demonstrated by linked data from New South Wales (NSW), Australia.

Authors:  Elizabeth Buckley; Elisabeth Elder; Sarah McGill; Zahra Shahabi Kargar; Ming Li; David Roder; David Currow
Journal:  Breast Cancer Res Treat       Date:  2021-03-21       Impact factor: 4.872

3.  Urban-rural disparity of generics prescription in Taiwan: the example of dihydropyridine derivatives.

Authors:  Chia-Chen Hsu; Chia-Lin Chou; Shu-Chiung Chiang; Tzeng-Ji Chen; Li-Fang Chou; Yueh-Ching Chou
Journal:  ScientificWorldJournal       Date:  2014-02-10

Review 4.  Understanding the effects of socioeconomic status along the breast cancer continuum in Australian women: a systematic review of evidence.

Authors:  Greg Lyle; Gilly A Hendrie; Delia Hendrie
Journal:  Int J Equity Health       Date:  2017-10-16

5.  Variations in outcomes by residential location for women with breast cancer: a systematic review.

Authors:  Paramita Dasgupta; Peter D Baade; Danny R Youlden; Gail Garvey; Joanne F Aitken; Isabella Wallington; Jennifer Chynoweth; Helen Zorbas; Philippa H Youl
Journal:  BMJ Open       Date:  2018-04-29       Impact factor: 2.692

6.  Geographical Inequalities in Surgical Treatment for Localized Female Breast Cancer, Queensland, Australia 1997-2011: Improvements over Time but Inequalities Remain.

Authors:  Peter D Baade; Paramita Dasgupta; Philippa H Youl; Christopher Pyke; Joanne F Aitken
Journal:  Int J Environ Res Public Health       Date:  2016-07-19       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.